Table Of ContentAccelerating Precision Medicine
January 19, 2018 | Courtyard Marriott Hotel | Toronto, Canada
Conference Handbook
Gold Sponsor Silver Sponsor Bronze Sponsors
TABLE OF CONTENTS
Welcome Letter from the Co-Chairs ........................................................................................... 2
General Information .................................................................................................................... 3
Faculty ....................................................................................................................................... 4
Program Agenda ........................................................................................................................ 5
Speaker Biographies .................................................................................................................. 8
Rapid Fire Abstracts (#1 – #18) ................................................................................................ 11
Poster Abstracts (#19 - #83) ..................................................................................................... 12
Abstracts .................................................................................................................................. 16
Note Pages .............................................................................................................................. 97
Sponsors ................................................................................................................................ 101
The materials contained in this conference handbook in addition to any videos that may be
presented are not authorized to be reproduced, recorded, transmitted, distributed or displayed,
without expressed consent from the presenter. For more information, contact Conference
Services at (416) 597-3422 extension 3844 or [email protected].
1
WELCOME FROM THE CO-CHAIRS
Dear Delegates:
Welcome to the Princess Margaret Cancer Centre - Accelerating Precision Medicine in 2018
Conference. We have an exciting program designed for you with two keynote speakers Dr. Myles
Brown, Director, Center for Functional Cancer Epigenetics and Dr. Pasi Jänne, Director of the
Lower Center for Thoracic Oncology, both from Dana-Farber Cancer Institute. The day will be filled
with lectures and discussion around genomics, immunotherapy, artificial intelligence, and cancer
survivorship as well as rapid fire abstract presentations on a variety of topics. We will wrap up with
the official poster viewing at 4:15pm and reception.
All posters will be eligible for a prize. In your name badge you will see coloured stars which are to
be used for voting. During the course of the day, you are invited to view the posters and place a
star on the poster that you would like to see win. Voting will close at 4:00pm and the winners will
be announced during the Reception.
We look forward to seeing you!
Sincerely,
Penelope Bradbury Mathieu Lupien
Conference Co-Chair Conference Co-Chair
Overall Conference Objectives
At the end of the conference, the participants will be able to:
• Explore technological advances to realize precision medicine.
• Review successful implementation practices for precision medicine in clinical practice.
• Propose novel solutions to realizing personalized medicine.
• Facilitate networking with our regional and international colleagues.
2
GENERAL INFORMATION
Accreditation
This continuing education event was held under the auspices of Continuing Professional
Development, Faculty of Medicine, University of Toronto and Princess Margaret Cancer Centre,
University Health Network.
Royal College of Physicians and Surgeons of Canada – Section 1:
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of
Certification Program of The Royal College of Physicians and Surgeons of Canada, approved by
Continuing Professional Development, Faculty of Medicine, University of Toronto. You may claim
up to a maximum of 6.5 hours (credits are automatically calculated).
Certificate of Attendance
To receive your certificate of attendance, you must complete the online evaluations (see
Evaluation section below). Upon completion, you will be directed to your certificate where you will
be able to type in your name, the number of credits you are eligible for, and print the certificate.
Please find a breakdown of the hours below:
Friday January 19: 6.5 hours
Evaluation
The evaluation will be done through an online survey that will be sent to you by the end of the
day. The email will include a link to the survey. The survey will be easily accessible on your smart
phone or you can choose to complete the survey online at your desktop computer/laptop. Please
note that if you open the survey, you must complete the survey in its entirety. If you close out of
the survey, it will not save. Once you complete the survey and click “Done”, you will be directed to
your certificate of attendance.
WiFi Access
The Courtyard Marriott Hotel has a password protected WiFi network through the meeting area.
To access your complimentary WiFi, open your device’s network settings, select
Courtyard_Conference, and enter the password PM2018 when prompted.
Information
Should you require assistance at any time during this conference, please visit the registration
desk, located in the foyer.
Poster Presentations
We invite you to view the posters during the breaks and lunch. The official poster viewing is
during the reception at 4:15 pm at which time all authors are asked to be present at their poster.
Please take the time to visit the authors and learn about their research. All posters are eligible for
a prize. Please use the stars provided in your name badge to vote for your favourite poster during
the breaks through the day. Voting will close at 4:00 pm and one winner will be announced during
the reception. Posters may be taken down after the reception at 5:15 pm. Any posters left behind
will be discarded.
3
FACULTY
Keynote Speakers
Myles Brown, MD Pasi A Jänne, MD, PhD
Director, Center for Functional Cancer Director of the Lower Center for Thoracic
Epigenetics Oncology
Dana-Farber Cancer Institute Dana-Farber Cancer Institute
Faculty
Cheryl Arrowsmith, PhD David Jaffray, PhD
Senior Scientist Director, Medical Physics
Princess Margaret Cancer Centre – UHN Princess Margaret Cancer Centre – UHN
Executive Vice President Technology &
Philippe Bedard, MD, FRCPC Innovation – UHN
Medical Oncologist
Princess Margaret Cancer Centre – UHN Jennifer Jones, PhD
Director of Research
Marcus Butler, MD Cancer Survivorship Program
Medical Oncologist Princess Margaret Cancer Centre – UHN
Princess Margaret Cancer Centre – UHN
Daniel DeCarvalho, PhD
Senior Scientist
Princess Margaret Cancer Centre – UHN
Planning Committee
Penny Bradbury, MB BCh FRACP MD
Medical Oncologist
Princess Margaret Cancer Centre – UHN
Meredith Giuliani, MBBS Med FRCPC
Radiation Oncologist
Director Cancer Education
Princess Margaret Cancer Centre – UHN
Mathieu Lupien, PhD
Senior Scientist
Princess Margaret Cancer Centre – UHN
4
PROGRAM AGENDA
Time Program Title
7:15 – 8:15 Breakfast and Registration
8:15 – 8:25 Welcome and Introductions
Mary Gospodarowicz
8:25 – 9:15 Moderator: Hansen He
Keynote Speaker
Drivers of Therapeutic Resistance and Synthetic Lethal Vulnerabilities
Myles Brown
Learning Objectives
At the end of this session, participants will be able to:
Differentiate between genetic, epigenetic and feedback mechanisms of resistance.
Describe the use of CRISPR screens to identify synthetic lethal vulnerabilities.
Identify new potential therapeutic targets.
9:15 – 9:50 Update from the Cancer Genomics Program
Philippe Bedard
Learning Objectives
At the end of this session, participants will be able to:
Review evidence for clinical utility of multi-gene sequencing in advanced solid
tumors.
Introduce Ontario-wide collaboration (OCTANE) to accelerate opportunities for
precision oncology.
9:50 – 10:20 Rapid Fire Presentations
Moderator: Mathieu Lupien
Learning Objectives
At the end of this session, participants will be able to:
Discuss high impact research projects from trainees.
Appreciate the breadth of personalized cancer medicine research.
9:50 – 9:55 1 - Development and Clinical Translation of a Handheld Imaging Device for 5-ALA
Fluorescence Guided Breast Conserving Surgery – Christopher Gibson
9:55 – 10:00 2 - Integration of Multiple Platforms To Discover Idh-Mutant Glioma Subtypes –
Yasin Mamatjan
10:00 – 10:05 3 - Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening –
Ruoshi Shi
10:05 – 10:10 4 - Investigating the Impact of Noncoding Mutations on Master Transcriptional Machinery
Through the Lens of the Primary Prostate Cancer Epigenome – Stanley Zhou
10:10 – 10:15 5 - Utilization of Methylated Circulating Tumour DNA in Oral Squamous Cell Carcinoma for
Non-invasive Tumour Methylome Profiling and Detection of Minimal Residual Disease –
Justin Burgener
10:15 – 10:20 6 - An Integrative DNA Sequencing Panel to Assess Sources of Mismatch Repair Deficiency
Leslie Oldfield
10:20 – 10:45 Morning Break and Poster Viewing
5
PROGRAM AGENDA
Time Program Title
10:45 – 11:15 Moderator: Faiyaz Notta
Immunotherapy Biomarkers of Response and Resistance
Marcus Butler
Learning Objectives
At the end of this session, participants will be able to:
Review patterns of response and resistance to immunotherapies.
Understand mechanisms and biomarkers of response and resistance.
11:15 – 11:45 Probing Cancer Epigenomes for Therapeutic Opportunities
Cheryl Arrowsmith
Learning Objectives
At the end of this session, participants will be able to:
Describe currently available chemical probes and drugs that target the epigenetic
regulatory machinery.
Provide examples of how epigenetic chemical probes can be used to identify
patient-specific epigenetic vulnerabilities in patient-derived cancer cells.
11:45 – 12:15 Rapid Fire Presentations
Moderator: Scott Bratman
Learning Objectives
At the end of this session, participants will be able to:
Discuss high impact research projects from trainees.
Appreciate the breadth of personalized cancer medicine research
11:45 – 11:50 7 - Pre-clinical Assessment of Radiation Response Using in vitro Dose Response and
Transcriptomic Data – Venkata Manem
11:50 – 11:55 8 - QIPCM Imaging Core Lab – A Robust Solution for Multi-Center Clinical Trials –
Viktor Iakovenko
11:55 – 12:00 9 - Molecular Targeting to Expand the Therapeutic Ratio in Women with Curable Cervical
Cancer – Naz Chaudary
12:00 – 12:05 10 - Development and Validation of a Platform for High Throughput Tissue Cytometry for
Quantitative Pathology Analysis on Immunostained Slides – Trevor McKee
12:05 – 12:10 11 - Investigating the Utility of Circulating Tumour DNA as a Biomarker of Treatment
Response in Head and Neck Squamous Cell Carcinoma – Ariana Rostami
12:10 – 12:15 12 - An Innovative Bench to Bedside Pipeline to Guide Selection and Testing of Patient
Reported Outcomes (PROs) for Personalized Symptom Management – Doris Howell
12:15 – 1:15 Lunch with Sponsors/Exhibitors and Poster Viewing
1:15 – 2:05 Moderator: Penny Bradbury
Keynote Speaker
New Therapeutic Strategies for EGFR Mutant Lung Cancer
Pasi A Jänne
Learning Objectives
At the end of this session, participants will be able to:
Identify current therapeutic gaps in the treatment of EGFR mutant lung cancer.
Describe ongoing and future strategies to improve treatment of EGFR mutant lung
cancer.
6
PROGRAM AGENDA
Time Program Title
2:05 – 2:35 Rapid Fire Presentations
Moderator: Rosemary Martino
Learning Objectives
At the end of this session, participants will be able to:
Discuss high impact research projects from trainees.
Appreciate the breadth of personalized cancer medicine research.
2:05 – 2:10 13 - Prevalence of Severe Dysphagia in Patients Up to 5 Years following Completion of
Curative Radiotherapy for Head and Neck Cancer – Elissa Greco
2:10 – 2:15 14 - Advantage of Non-uniform Loading of Episcleral plaque for Treatment of Uveal
Melanoma – Akbar Beiki-Ardakani
2:15 – 2:20 15 - Can Recurrence Patterns After Curative Resection for Gastric Adenocarcinoma (GCa)
Inform the Selection of Adjuvant Treatment? – Jossie M. Swett Cosentino
2:20 – 2:25 16 - Therapeic Targeting of Hypoxia Mediated Changes to the Epigenome in Prostate
Cancer – Sarina Cameron
2:25 – 2:30 17 - Targeted Photodynamic Pre-Treatment: a Novel to Strategy to Enhance Tumor
Accumulation of Nanomedicines – Marta Overchuk
2:30 – 2:35 18 - IFN-y Induces T cell Resistance Against Immunosuppression Regulatory T Cells in
CD8+ T cells, but not CD4+ T cells – Douglas C. Chung
2:35 – 2:45 Stretch Break
2:45 – 3:15 Moderator: Meredith Giuliani
Automation aka AI
David Jaffray
Learning Objectives
At the end of this session, participants will be able to:
Understand emerging technological shifts that enable automation.
Learn about examples of automation in cancer care.
Discuss key opportunities and challenges for automation in cancer care.
3:15 – 3:45 Adult Cancer Survivors: Restoring Health and Well-Being
Jennifer Jones
Learning Objectives
At the end of this session, participants will be able to:
Review the current knowledge base on the issues and challenges adult cancer
survivors face during re-entry and later phases of the cancer survivor trajectory.
Highlight the essential components of survivorship care necessary to ensure that
supportive care and health care needs of survivors are appropriately addressed.
3:45 – 4:15 Highly Sensitive Tumor Detection and Classification using Methyloma Analysis of
Plasma cfDNA
Daniel DeCarvalho
Learning Objectives
At the end of this session, participants will be able to:
Appreciate the potential of liquid biopsy for non-invasive cancer detection and
classification.
Appreciate the sensitivity limitations of detecting mutations on plasma cell-free
circulating tumor DNA and the potential of DNA Methylation to improve sensitivity.
4:15 – 5:15 Poster Viewing and Reception
7
SPEAKER BIOGRAPHIES
Keynote Speakers
Myles Brown, MD
Myles Brown obtained his undergraduate degree in Biology from Yale University and
his M.D. from the Johns Hopkins University School of Medicine. He completed
training in Internal Medicine at the Brigham and Women's Hospital while doing
research with David Livingston at the Dana-Farber. He went on to complete training
in Medical Oncology at the Dana-Farber and postdoctoral research with Phillip Sharp
at MIT. Following the completion of his training he joined the faculty of the Dana-
Farber and Harvard Medical School. From 2002-2010 he served as Chief of the
Division of Molecular and Cellular Oncology at the Dana-Farber. In 2010 together with Shirley Liu he
founded the Center for Functional Cancer Epigenetics at the Dana-Farber.
Pasi A Jänne, MD, PhD
Pasi Jänne is the Director of the Lower Center for Thoracic Oncology at Dana Farber
Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also
the Director of the Belfer Center for Applied Cancer Science at the Dana Farber
Cancer Institute. After earning his MD and PhD from the School of Medicine at the
University of Pennsylvania, Dr Jänne completed his internship and residency in
Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed
fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital
combined program in medical oncology in 2001. In 2002 he earned a Masters Degree in clinical
investigation from Harvard University.
Dr Jänne’s research combines laboratory based studies, with translational research and clinical
trials of novel therapeutic agents in patients with lung cancer. His main research interests center
around understanding and translating the therapeutic importance of oncogenic alterations in lung
cancer. He has made seminal therapeutic discoveries, including being on one of the co-discoverers
of EGFR mutations, and findings from his work has led to the development of several clinical trials.
In addition, he led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib
which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several
awards for his research, including from Uniting Against Lung Cancer, American Lung Association,
and the Bonnie J. Addario Lung Cancer Foundation. He is an elected member to the American
Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish
Academy of Science and Letters (2016). Dr. Jänne is also the recipient of 2010 American
Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a member of
the 2010 AACR Team Science Award. In 2017 he was awarded an American Cancer Society
Clinical Research Professorship.
8
SPEAKER BIOGRAPHIES
Plenary Speakers
Cheryl Arrowsmith, PhD
Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre and
Professor in the Department of Medical Biophysics. She received a Ph.D. in
chemistry from the University of Toronto and carried out postdoctoral research at
Stanford University in the area of protein NMR spectroscopy. Dr. Arrowsmith’s
research focuses on structural and chemical biology of chromatin and epigenetic
regulatory factors especially as relates to cancer. Dr. Arrowsmith is the Chief
Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a
multinational public-private partnership that supports the discovery of new medicines through
protein-based open access research. She leads the SGC’s program to develop chemical probes to
chromatin regulators for target validation.
Philippe Bedard, MD, FRCPC
Philippe Bedard is an Assistant Professor of Medicine at the University of Toronto.
He is a Staff Medical Oncologist in the Division of Medical Oncology and the
Fellowship Director for the Bras Family New Drug Development Program at the
Princess Margaret Cancer Centre.
Dr. Bedard received his medical degree from the University of Toronto where he was
awarded the Cody Academic Silver Medal. He completed his Internal Medicine and
Medical Oncology specialty training at the University of Toronto. Dr. Bedard received additional
fellowship training in clinical and translational research at the Breast International Group (BIG). The
Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) recognised him
with a 2012 Career Development Award.
Dr. Bedard's clinical practice includes the treatment of patients with breast and testicular cancers. As
the Clinical Director for the Cancer Genomics Program at the Princess Margaret Cancer Centre, his
research involves early phase clinical trials and the personalisation of cancer treatment based upon
the results of testing for DNA mutations within tumour cells.
Marcus Butler, MD
Marcus Butler is a physician investigator with an interest in the translational
development of immune-based therapies for cancer patients. He is a member of the
medical oncology staff at Princess Margaret Cancer Centre and is an Assistant
Professor at the University of Toronto. He cares for patients with melanoma and
gynecologic malignancies and is the clinical director of the Princess Margaret
Immune Monitoring Laboratory. His work focuses on the development of
immunotherapy trials, which include studies, alone and in combination, of immune
checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.
9
